Search

Your search keyword '"Bunn, Paul A Jr"' showing total 330 results
Start Over Author "Bunn, Paul A Jr"
330 results on '"Bunn, Paul A Jr"'

1. Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study

Author

Dacic, Sanja, Travis, William D., Giltnane, Jennifer M., Kos, Filip, Abel, John, Hilz, Stephanie, Fujimoto, Junya, Sholl, Lynette, Ritter, Jon, Khalil, Farah, Liu, Yi, Taylor-Weiner, Amaro, Resnick, Murray, Yu, Hui, Hirsch, Fred R., Bunn, Paul A., Jr., Carbone, David P., Rusch, Valerie, Kwiatkowski, David J., Johnson, Bruce E., Lee, Jay M., Hennek, Stephanie R., Wapinski, Ilan, Nicholas, Alan, Johnson, Ann, Schulze, Katja, Kris, Mark G., and Wistuba, Ignacio I.

Published
2024
Full Text
View/download PDF

2. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy

Author

Dacic, Sanja, Travis, William, Redman, Mary, Saqi, Anjali, Cooper, Wendy A., Borczuk, Alain, Chung, Jin-Haeng, Glass, Carolyn, Lopez, Javier Martin, Roden, Anja C., Sholl, Lynette, Weissferdt, Annikka, Posadas, Juan, Walker, Angela, Zhu, Hu, Wijeratne, Manuja T., Connolly, Casey, Wynes, Murry, Bota-Rabassedas, Neus, Sanchez-Espiridion, Beatriz, Lee, J.Jack, Berezowska, Sabina, Chou, Teh-Ying, Kerr, Keith, Nicholson, Andrew, Poleri, Claudia, Schalper, Kurt A., Tsao, Ming-Sound, Carbone, David P., Ready, Neal, Cascone, Tina, Heymach, John, Sepesi, Boris, Shu, Catherine, Rizvi, Naiyer, Sonett, Josuha, Altorki, Nasser, Provencio, Mariano, Bunn, Paul A., Jr., Kris, Mark G., Belani, Chandra P., Kelly, Karen, and Wistuba, Ignacio

Published
2023
Full Text
View/download PDF

3. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Author

Rolfo, Christian, Meshulami, Noy, Russo, Alessandro, Krammer, Florian, García-Sastre, Adolfo, Mack, Philip C., Gomez, Jorge E., Bhardwaj, Nina, Benyounes, Amin, Sirera, Rafael, Moore, Amy, Rohs, Nicholas, Henschke, Claudia I., Yankelevitz, David, King, Jennifer, Shyr, Yu, Bunn, Paul A., Jr., Minna, John D., and Hirsch, Fred R.

Published
2022
Full Text
View/download PDF

4. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

Author

Wang, Shidan, Rong, Ruichen, Yang, Donghan M., Fujimoto, Junya, Bishop, Justin A., Yan, Shirley, Cai, Ling, Behrens, Carmen, Berry, Lynne D., Wilhelm, Clare, Aisner, Dara, Sholl, Lynette, Johnson, Bruce E., Kwiatkowski, David J., Wistuba, Ignacio I., Bunn, Paul A., Jr., Minna, John, Xiao, Guanghua, Kris, Mark G., and Xie, Yang

Subjects
Oncology, Experimental, Gene mutations -- Research, Lung cancer -- Genetic aspects -- Drug therapy -- Prognosis, Machine learning -- Usage, Cell interaction -- Research, Cancer -- Research, Algorithms -- Usage, Algorithm, Health care industry
Abstract

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective for many patients with lung cancer with EGFR mutations. However, not all patients are responsive to EGFR TKIs, including even those harboring EGFR-sensitizing mutations. In this study, we quantified the cells and cellular interaction features of the tumor microenvironment (TME) using routine H&E-stained biopsy sections. These TME features were used to develop a prediction model for survival benefit from EGFR TKI therapy in patients with lung adenocarcinoma and EGFR-sensitizing mutations in the Lung Cancer Mutation Consortium 1 (LCMC1) and validated in an independent LCMC2 cohort. In the validation data set, EGFR TKI treatment prolonged survival in the predicted-to-benefit group but not in the predicted-not-to-benefit group. Among patients treated with EGFR TKIs, the predicted-to-benefit group had prolonged survival outcomes compared with the predicted not-to- benefit group. The EGFR TKI survival benefit positively correlated with tumor- tumor interaction image features and negatively correlated with tumor-stroma interaction. Moreover, the tumor-stroma interaction was associated with higher activation of the hepatocyte growth factor/MET-mediated PI3K/AKT signaling pathway and epithelial-mesenchymal transition process, supporting the hypothesis of fibroblast-involved resistance to EGFR TKI treatment., Introduction Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have shown survival improvements in the treatment of patients with EGFR-mutant lung cancer as first line therapy. Erlotinib, [...]

Published
2023
Full Text
View/download PDF

5. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Author

Blumenthal, Gideon M., Bunn, Paul A., Jr., Chaft, Jamie E., McCoach, Caroline E., Perez, Edith A., Scagliotti, Giorgio V., Carbone, David P., Aerts, Hugo J.W.L., Aisner, Dara L., Bergh, Jonas, Berry, Donald A., Jarkowski, Anthony, Botwood, Nicholas, Cross, Darren A.E., Diehn, Max, Drezner, Nicole L., Doebele, Robert C., Blakely, Collin M., Eberhardt, Wilfried E.E., Felip, Enriqueta, Gianni, Luca, Keller, Steven P., Leavey, Patrick J., Malik, Shakun, Pignatti, Francesco, Prowell, Tatiana M., Redman, Mary W., Rizvi, Naiyer A., Rosell, Rafael, Rusch, Valerie, de Ruysscher, Dirk, Schwartz, Lawrence H., Sridhara, Rajeshwari, Stahel, Rolf A., Swisher, Stephen, Taube, Janis M., Travis, William D., Keegan, Patricia, Wiens, Jacinta R., Wistuba, Ignacio I., Wynes, Murry W., Hirsch, Fred R., and Kris, Mark G.

Published
2018
Full Text
View/download PDF

6. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Author

Hirsch, Fred R., Kerr, Keith M., Bunn, Paul A., Jr., Kim, Edward S., Obasaju, Coleman, Pérol, Maurice, Bonomi, Philip, Bradley, Jeffrey D., Gandara, David, Jett, James R., Langer, Corey J., Natale, Ronald B., Novello, Silvia, Paz-Ares, Luis, Ramalingam, Suresh S., Reck, Martin, Reynolds, Craig H., Smit, Egbert F., Socinski, Mark A., Spigel, David R., Stinchcombe, Thomas E., Vansteenkiste, Johan F., Wakelee, Heather, and Thatcher, Nick

Published
2018
Full Text
View/download PDF

9. New Developments in Neoadjuvant Therapy for Lung Cancer

Author

Bunn, Paul A., Jr., Schenk, Erin, Pacheco, Jose, and Dimou, Anastasios

Subjects
Immunotherapy -- Methods, Lung cancer -- Care and treatment, Molecular targeted therapy -- Methods, Neoadjuvant therapy -- Methods, Chemotherapy, Cancer treatment, Adjuvant chemotherapy, Ipilimumab, Cancer metastasis, Clinical trials, Carboplatin, Health
Abstract

Lung cancer is the leading cause of cancer death in the United States and worldwide. While most patients present with advanced metastatic disease for which a cure is elusive, increased use of spiral CT screening has led to identification of more early-stage patients who can be treated. At the same time, immunotherapy and new targeted therapies have improved survival in advanced disease. These new therapies are now being studied in the neoadjuvant and adjuvant settings to reduce systemic recurrences and improve cure rates. The results of early clinical trials of checkpoint inhibitor immunotherapy alone and combined with chemotherapy, as well as those of neoadjuvant studies of molecular therapies, have been promising. Ongoing large neoadjuvant trials of immunotherapies and molecular therapies alone and in combination with chemotherapy are underway and eagerly awaited. In this article, we review these new developments in neoadjuvant therapy for lung cancer., Introduction While surgical resection of early-stage lung cancer cures some patients, only a minority remain recurrence-free at 5 years.[1] Multiple trials have shown that the majority of recurrences are in [...]

Published
2019

11. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Author

Tan, Daniel S.W., Yom, Sue S., Tsao, Ming S., Pass, Harvey I., Kelly, Karen, Peled, Nir, Yung, Rex C., Wistuba, Ignacio I., Yatabe, Yasushi, Unger, Michael, Mack, Philip C., Wynes, Murry W., Mitsudomi, Tetsuya, Weder, Walter, Yankelevitz, David, Herbst, Roy S., Gandara, David R., Carbone, David P., Bunn, Paul A., Jr., Mok, Tony S.K., and Hirsch, Fred R.

Published
2016
Full Text
View/download PDF

12. Scientific Advances in Lung Cancer 2015

Author

Tsao, Anne S., Scagliotti, Giorgio V., Bunn, Paul A., Jr., Carbone, David P., Warren, Graham W., Bai, Chunxue, de Koning, Harry J., Yousaf-Khan, A. Uraujh, McWilliams, Annette, Tsao, Ming Sound, Adusumilli, Prasad S., Rami-Porta, Ramón, Asamura, Hisao, Van Schil, Paul E., Darling, Gail E., Ramalingam, Suresh S., Gomez, Daniel R., Rosenzweig, Kenneth E., Zimmermann, Stefan, Peters, Solange, Ignatius Ou, Sai-Hong, Reungwetwattana, Thanyanan, Jänne, Pasi A., Mok, Tony S., Wakelee, Heather A., Pirker, Robert, Mazières, Julien, Brahmer, Julie R., Zhou, Yang, Herbst, Roy S., Papadimitrakopoulou, Vassiliki A., Redman, Mary W., Wynes, Murry W., Gandara, David R., Kelly, Ronan J., Hirsch, Fred R., and Pass, Harvey I.

Published
2016
Full Text
View/download PDF

13. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Author

Bunn, Paul A., Jr., Minna, John D., Augustyn, Alexander, Gazdar, Adi F., Ouadah, Youcef, Krasnow, Mark A., Berns, Anton, Brambilla, Elisabeth, Rekhtman, Natasha, Massion, Pierre P., Niederst, Matthew, Peifer, Martin, Yokota, Jun, Govindan, Ramaswamy, Poirier, John T., Byers, Lauren A., Wynes, Murry W., McFadden, David G., MacPherson, David, Hann, Christine L., Farago, Anna F., Dive, Caroline, Teicher, Beverly A., Peacock, Craig D., Johnson, Jane E., Cobb, Melanie H., Wendel, Hans-Guido, Spigel, David, Sage, Julien, Yang, Ping, Pietanza, M. Catherine, Krug, Lee M., Heymach, John, Ujhazy, Peter, Zhou, Caicun, Goto, Koichi, Dowlati, Afshin, Christensen, Camilla Laulund, Park, Keunchil, Einhorn, Lawrence H., Edelman, Martin J., Giaccone, Giuseppe, Gerber, David E., Salgia, Ravi, Owonikoko, Taofeek, Malik, Shakun, Karachaliou, Niki, Gandara, David R., Slotman, Ben J., Blackhall, Fiona, Goss, Glenwood, Thomas, Roman, Rudin, Charles M., and Hirsch, Fred R.

Published
2016
Full Text
View/download PDF

14. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

Author

Rodilla, Ananda M., Valanparambil, Rajesh M., Mack, Philip C., Hsu, Chih-Yuan, Cagan, Jazz, Tavolacci, Sooyun C., Carreño, Juan Manuel, Brody, Rachel, Moore, Amy, King, Jennifer C., Gomez, Jorge E., Rohs, Nicholas, Rolfo, Christian, Bunn, Paul A., Jr., Gerber, David E., Minna, John D., Krammer, Florian, Ramalingam, Suresh S., García-Sastre, Adolfo, Shyr, Yu, Ahmed, Rafi, and Hirsch, Fred R.

Published
2023
Full Text
View/download PDF

15. Prostacyclin and Lung Cancer Chemoprevention

Author

Keith, Robert L., Miller, York E., Bunn, Paul A., Jr., Nana-Sinkam, Patrick, Nemenoff, Raphael A., Geraci, Mark W., Teicher, Beverly A., editor, Kelloff, Gary J., editor, Hawk, Ernest T., editor, and Sigman, Caroline C., editor

Published
2004
Full Text
View/download PDF

18. Lung Cancer

Author

William de Araujo, Carlos, Bunn, Paul A., Jr, Kirkwood, John M., Lotze, Michael T., and Yasko, Joyce M.

Published
2001
Full Text
View/download PDF

20. Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Author

Andre, D., Alshammary, H., van Bakel, H., Bermúdez-González, M.C., Cai, G., Cognigni, C., Floda, D., Firpo, A., Kleiner, G., Lyttle, N., Mendez, W., Mulder, L.C.F., Oostenink, A., Rooker, A., Salimbangon, A., Saksena, M., Sominsky, L., Sordillo, E.M., Mack, Philip C., Gomez, Jorge E., Rodilla, Ananda M., Carreño, Juan Manuel, Hsu, Chih-Yuan, Rolfo, Christian, Meshulami, Noy, Moore, Amy, Brody, Rachel I., King, Jennifer C., Treatman, Jacquelyn, Lee, Sooyun, Raskin, Ariel, Srivastava, Komal, Gleason, Charles R., de Miguel-Perez, Diego, Tcheou, Johnstone, Bielak, Dominika, Acharya, Rashmi, Gerber, David E., Rohs, Nicholas, Henschke, Claudia I., Yankelevitz, David F., Simon, Viviana, Minna, John D., Bunn, Paul A., Jr., García-Sastre, Adolfo, Krammer, Florian, Shyr, Yu, and Hirsch, Fred R.

Published
2022
Full Text
View/download PDF

41. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer

Author

Hirsch, Fred R., Dziadziuszko, Rafal, Thatcher, Nick, Mann, Helen, Watkins, Claire, Parums, Dinah V., Speake, Georgina, Holloway, Brian, Bunn, Paul A., Jr., and Franklin, Wilbur A.

Subjects
Lung cancer, Non-small cell -- Development and progression, Lung cancer, Non-small cell -- Care and treatment, Lung cancer, Non-small cell -- Research, Gefitinib -- Dosage and administration, Gefitinib -- Research, Immunohistochemistry -- Research, Immune response -- Research, Biological markers -- Analysis, Health
Published
2008

42. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study

Author

Taguchi, Fumiko, Solomon, Benjamin, Gregorc, Vanesa, Roder, Heinrich, Gray, Robert, Kasahara, Kazuo, Nishio, Makoto, Brahmer, Julie, Spreafico, Anna, Ludovini, Vienna, Massion, Pierre P., Dziadziuszko, Rafal, Schiller, Joan, Grigorieva, Julia, Tsypin, Maxim, Hunsucker, Stephen W., Caprioli, Richard, Duncan, Mark W., Hirsch, Fred R., Bunn, Paul A., Jr., and Carbone, David P.

Subjects
Lung cancer, Non-small cell -- Research, Lung cancer, Non-small cell -- Care and treatment, Lung cancer, Non-small cell -- Complications and side effects, Lung cancer, Non-small cell -- Analysis, Health
Abstract

Background Some but not all patients with non-small-cell lung cancer (NSCLC) respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We developed and tested the ability of a predictive algorithm based on matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) analysis of pretreatment serum to identify patients who are likely to benefit from treatment with EGFR TKIs. Methods Serum collected from NSCLC patients before treatment with gefitinib or erlotinib were analyzed by MALDI MS. Spectra were acquired independently at two institutions. An algorithm to predict outcomes after treatment with EGFR TKIs was developed from a training set of 139 patients from three cohorts. The algorithm was then tested in two independent validation cohorts of 67 and 96 patients who were treated with gefitinib and erlotinib, respectively, and in three control cohorts of patients who were not treated with EGFR TKIs. The clinical outcomes of survival and time to progression were analyzed. Results An algorithm based on eight distinct m/z features was developed based on outcomes after EGFR TKI therapy in training set patients. Classifications based on spectra acquired at the two institutions had a concordance of 97.1%. For both validation cohorts, the classifier identified patients who showed improved outcomes after EGFR TKI treatment. In one cohort, median survival of patients in the predicted 'good' and 'poor' groups was 207 and 92 days, respectively (hazard ratio [HR] of death in the good versus poor groups = 0.50, 95% confidence interval [CI] = 0.24 to 0.78). In the other cohort, median survivals were 306 versus 107 days (HR = 0.41, 95% CI = 0.17 to 0.63). The classifier did not predict outcomes in patients who did not receive EGFR TKI treatment. Conclusion This MALDI MS algorithm was not merely prognostic but could classify NSCLC patients for good or poor outcomes after treatment with EGFR TKIs. This algorithm may thus assist in the pretreatment selection of appropriate subgroups of NSCLC patients for treatment with EGFR TKIs.

Published
2007

45. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

Author

Cappuzzo, Federico, Hirsch, Fred R., Rossi, Elisa, Bartolini, Stefania, Ceresoli, Giovanni L., Bemis, Lynne, Haney, Jerry, Witta, Samir, Danenberg, Kathleen, Domenichini, Irene, Ludovini, Vienna, Magrini, Elisabetta, Gregorc, Vanesa, Doglioni, Claudio, Sidoni, Angelo, Tonato, Maurizio, Franklin, Wilbur A., Crino, Lucio, Bunn, Paul A. Jr., and Varella-Garcia, Marileila

Subjects
Lung cancer, Non-small cell -- Drug therapy, Health, Gefitinib (Medication) -- Research, Gefitinib (Medication) -- Usage
Abstract

Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC. Methods: Tumors from 102 NSCLC patients treated daily with 250 mg of gefitinib were evaluated for EGFR status by fluorescence in situ hybridization (FISH), DNA sequencing, and immunohistochemistry and for Akt activation status (phospho-Akt [P-Akt]) by immunohistochemistry. Time to progression, overall survival, and 95% confidence intervals (CIs) were calculated and evaluated by the Kaplan-Meier method; groups were compared using the log-rank test. Risk factors associated with survival were evaluated using Cox proportional hazards regression modeling and multivariable analysis. All statistical tests were two-sided. Results: Amplification or high polysomy of the EGFR gene (seen in 33 of 102 patients) and high protein expression (seen in 58 of 98 patients) were statistically significantly associated with better response (36% versus 3%, mean difference = 34%, 95% CI = 16.6 to 50.3; P

Published
2005

46. Introduction

Author

Bunn, Paul A., Jr., Veronesi, Umberto, editor, and Bunn, Paul A., Jr., editor

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results